Ушбу иш иқтибос қилган ишлар

69 та иш

Иш: Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)

1. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

   Irene Stratton

   Мақола20004 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.472208

2. NAFLD: Mechanisms, Treatments, and Biomarkers

   Fatiha Nassir

   Шарҳ мақола20224 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.519185

3. Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy

   Ashot Avagimyan, Mohammad Sheibani, Nana Pogosova +8

   Мақола20233 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.282558

4. Strategies to Tackle the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence

   Tien Yin Wong, Charumathi Sabanayagam

   Шарҳ мақола20192 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.014939

5. A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors

   Christopher Cunningham, Ahmad Jabri, Laith Alhuneafat +1

   Шарҳ мақола20232 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.282552

6. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials

   Karan B. Bhanushali, Heena Asnani, Ambica Nair +2

   Шарҳ мақола20242 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.282571

7. Anthracycline Associated Disturbances of Cardiovascular Homeostasis

   Ashot Avagimyan, Lev Kakturskiy, Kiyan Heshmat‐Ghahdarijani +2

   Шарҳ мақола20212 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.416834

8. Comparison of Cardioprotective Effects of Dapagliflozin and Trimetazidine in the Model of Doxorubicin-Cyclophosphamide Cardiotoxicity

   Ashot Avagimyan, А. И. Трофименко, Mohammad Sheibani +11

   МақолаChemotherapy-induced cardiotoxicity and mitigationInnovative medicine of Kuban20231 иқтибос

   ABIABI:AkademIndex/openalex/2023.article.001614

9. Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)

   Ashot Avagimyan, Mohammad Sheibani, А. И. Трофименко +15

   МақолаDiabetes Treatment and ManagementInnovative medicine of Kuban20241 иқтибос

   ABIABI:AkademIndex/openalex/2024.article.001048

10. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519153

11. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519154

12. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519155

13. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519156

14. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519157

15. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519158

16. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519159

17. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519160

18. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519161

19. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519162

20. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519163

21. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519164

22. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519165

23. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519166

24. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519167

25. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.519168